Dynavax Technologies Corporation (0IDA.L)
USD 13.78
(0.52%)
USD 13.78
(0.52%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 219.14 Million USD | 16.75% |
| 2022 | 178 Million USD | 34.46% |
| 2021 | 132.38 Million USD | 22.73% |
| 2020 | 107.86 Million USD | -21.45% |
| 2019 | 137.31 Million USD | -1.72% |
| 2018 | 139.72 Million USD | 49.36% |
| 2017 | 93.54 Million USD | -23.16% |
| 2016 | 121.75 Million USD | 11.57% |
| 2015 | 109.12 Million USD | 6.62% |
| 2014 | 102.34 Million USD | 31.65% |
| 2013 | 77.73 Million USD | 0.55% |
| 2012 | 77.31 Million USD | 11.73% |
| 2011 | 69.19 Million USD | -3.28% |
| 2010 | 71.53 Million USD | 29.05% |
| 2009 | 55.43 Million USD | -9.44% |
| 2008 | 61.21 Million USD | -28.14% |
| 2007 | 85.18 Million USD | 29.76% |
| 2006 | 65.65 Million USD | 76.74% |
| 2005 | 37.14 Million USD | 17.28% |
| 2004 | 31.67 Million USD | 70.37% |
| 2003 | 18.59 Million USD | -7.45% |
| 2002 | 20.08 Million USD | -8.24% |
| 2001 | 21.89 Million USD | 86.81% |
| 2000 | 11.71 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 55.75 Million USD | -1.16% |
| 2024 Q1 | 56.4 Million USD | 1.82% |
| 2023 Q4 | 55.39 Million USD | 6.19% |
| 2023 Q3 | 52.16 Million USD | 4.09% |
| 2023 Q2 | 50.11 Million USD | -0.06% |
| 2023 Q1 | 50.14 Million USD | 14.31% |
| 2023 FY | 207.83 Million USD | 16.75% |
| 2022 FY | 178 Million USD | 34.46% |
| 2022 Q4 | 43.86 Million USD | -2.52% |
| 2022 Q1 | 43.26 Million USD | 7.25% |
| 2022 Q2 | 45.86 Million USD | 6.01% |
| 2022 Q3 | 45 Million USD | -1.88% |
| 2021 Q4 | 40.34 Million USD | 21.83% |
| 2021 Q1 | 30.18 Million USD | 10.2% |
| 2021 Q2 | 28.75 Million USD | -4.74% |
| 2021 Q3 | 33.11 Million USD | 15.17% |
| 2021 FY | 132.38 Million USD | 22.73% |
| 2020 Q4 | 27.38 Million USD | -8.89% |
| 2020 FY | 107.86 Million USD | -21.45% |
| 2020 Q3 | 30.05 Million USD | 21.02% |
| 2020 Q1 | 25.57 Million USD | -21.51% |
| 2020 Q2 | 24.83 Million USD | -2.9% |
| 2019 Q2 | 34.05 Million USD | -13.9% |
| 2019 FY | 137.31 Million USD | -1.72% |
| 2019 Q1 | 39.55 Million USD | 0.57% |
| 2019 Q3 | 31.11 Million USD | -8.63% |
| 2019 Q4 | 32.58 Million USD | 4.72% |
| 2018 Q3 | 32.6 Million USD | 2.14% |
| 2018 FY | 139.72 Million USD | 49.36% |
| 2018 Q4 | 39.33 Million USD | 20.61% |
| 2018 Q1 | 35.85 Million USD | 28.69% |
| 2018 Q2 | 31.92 Million USD | -10.96% |
| 2017 Q4 | 27.86 Million USD | 24.14% |
| 2017 Q2 | 20.42 Million USD | -10.48% |
| 2017 Q3 | 22.44 Million USD | 9.88% |
| 2017 Q1 | 22.81 Million USD | -14.26% |
| 2017 FY | 93.54 Million USD | -23.16% |
| 2016 Q4 | 26.61 Million USD | -23.96% |
| 2016 Q2 | 31.9 Million USD | 12.98% |
| 2016 Q1 | 28.23 Million USD | 2.19% |
| 2016 FY | 121.75 Million USD | 11.57% |
| 2016 Q3 | 35 Million USD | 9.71% |
| 2015 Q4 | 27.63 Million USD | -6.74% |
| 2015 Q3 | 29.62 Million USD | 19.55% |
| 2015 FY | 109.12 Million USD | 6.62% |
| 2015 Q2 | 24.78 Million USD | -8.48% |
| 2015 Q1 | 27.07 Million USD | 9.68% |
| 2014 Q1 | 17.46 Million USD | 10.27% |
| 2014 FY | 102.34 Million USD | 31.65% |
| 2014 Q2 | 27.9 Million USD | 59.76% |
| 2014 Q4 | 24.69 Million USD | -23.53% |
| 2014 Q3 | 32.28 Million USD | 15.71% |
| 2013 Q2 | 20.44 Million USD | -10.99% |
| 2013 Q4 | 15.83 Million USD | -14.36% |
| 2013 FY | 77.73 Million USD | 0.55% |
| 2013 Q3 | 18.49 Million USD | -9.52% |
| 2013 Q1 | 22.96 Million USD | 5.3% |
| 2012 FY | 77.31 Million USD | 11.73% |
| 2012 Q1 | 18.19 Million USD | 12.6% |
| 2012 Q2 | 17.33 Million USD | -4.75% |
| 2012 Q3 | 19.97 Million USD | 15.22% |
| 2012 Q4 | 21.8 Million USD | 9.2% |
| 2011 Q4 | 16.16 Million USD | 1.04% |
| 2011 Q3 | 15.99 Million USD | -7.9% |
| 2011 Q2 | 17.36 Million USD | -11.72% |
| 2011 Q1 | 19.67 Million USD | 13.18% |
| 2011 FY | 69.19 Million USD | -3.28% |
| 2010 Q2 | 18.46 Million USD | 6.75% |
| 2010 FY | 71.53 Million USD | 29.05% |
| 2010 Q4 | 17.38 Million USD | -5.54% |
| 2010 Q3 | 18.4 Million USD | -0.34% |
| 2010 Q1 | 17.29 Million USD | 25.3% |
| 2009 FY | 55.43 Million USD | -9.44% |
| 2009 Q1 | 15 Million USD | 49.22% |
| 2009 Q2 | 13.01 Million USD | -13.23% |
| 2009 Q3 | 13.61 Million USD | 4.57% |
| 2009 Q4 | 13.8 Million USD | 1.4% |
| 2008 FY | 61.21 Million USD | -28.14% |
| 2008 Q4 | 10.05 Million USD | -31.21% |
| 2008 Q3 | 14.61 Million USD | -12.02% |
| 2008 Q2 | 16.61 Million USD | -16.68% |
| 2008 Q1 | 19.93 Million USD | -14.48% |
| 2007 Q2 | 23.62 Million USD | 30.78% |
| 2007 Q1 | 18.06 Million USD | -26.06% |
| 2007 Q3 | 20.18 Million USD | -14.53% |
| 2007 Q4 | 23.31 Million USD | 15.47% |
| 2007 FY | 85.18 Million USD | 29.76% |
| 2006 Q4 | 24.42 Million USD | 38.11% |
| 2006 FY | 65.65 Million USD | 76.74% |
| 2006 Q1 | 9.19 Million USD | -8.67% |
| 2006 Q3 | 17.68 Million USD | 23.36% |
| 2006 Q2 | 14.33 Million USD | 55.93% |
| 2005 Q1 | 7.99 Million USD | 0.57% |
| 2005 FY | 37.14 Million USD | 17.28% |
| 2005 Q4 | 10.06 Million USD | 10.44% |
| 2005 Q3 | 9.11 Million USD | -8.53% |
| 2005 Q2 | 9.96 Million USD | 24.65% |
| 2004 Q4 | 7.95 Million USD | 0.06% |
| 2004 FY | 31.67 Million USD | 70.37% |
| 2004 Q3 | 7.94 Million USD | -7.48% |
| 2004 Q2 | 8.58 Million USD | 19.43% |
| 2004 Q1 | 7.19 Million USD | 138.68% |
| 2003 FY | 18.59 Million USD | -7.45% |
| 2003 Q4 | -18.59 Million USD | 0.0% |
| 2003 Q1 | -4.71 Million USD | 0.0% |
| 2003 Q2 | - USD | 100.0% |
| 2003 Q3 | - USD | 0.0% |
| 2002 FY | 20.08 Million USD | -8.24% |
| 2001 FY | 21.89 Million USD | 86.81% |
| 2000 FY | 11.71 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | 23.13% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -351.827% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 46.394% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 87.826% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 48.756% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -293.043% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 20.511% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 87.451% |
| bluebird bio, Inc. | 240.23 Million USD | 8.778% |
| Blueprint Medicines Corporation | 722.86 Million USD | 69.684% |
| Adicet Bio, Inc. | 152.03 Million USD | -44.138% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 40.549% |
| Editas Medicine, Inc. | 247.3 Million USD | 11.386% |
| FibroGen, Inc. | 398.11 Million USD | 44.954% |
| Geron Corporation | 70.44 Million USD | -211.104% |
| Illumina, Inc. | 3.81 Billion USD | 94.253% |
| Insmed Incorporated | 949.26 Million USD | 76.914% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 60.269% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 71.89% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 89.326% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 79.884% |
| Evolus, Inc. | 189.75 Million USD | -15.486% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 86.273% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 83.896% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 58.575% |
| Verastem, Inc. | 92.08 Million USD | -137.984% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.46% |
| Zoetis Inc. | 2.76 Billion USD | 92.074% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 97.863% |
| Biogen Inc. | 5.2 Billion USD | 95.79% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 4.17% |
| Perrigo Company plc | 1.52 Billion USD | 85.663% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 89.639% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 51.408% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -53.826% |
| Myriad Genetics, Inc. | 600.1 Million USD | 63.482% |
| Waters Corporation | 943.51 Million USD | 76.774% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -1705.0% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -459.714% |
| Nektar Therapeutics | 190.9 Million USD | -14.794% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -117.348% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -390.619% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 53.996% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -81.626% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 95.411% |
| Imunon, Inc. | 21.03 Million USD | -942.038% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1475.49% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 19.401% |
| Homology Medicines, Inc. | 9.87 Million USD | -2119.19% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 92.216% |
| OPKO Health, Inc. | 574.68 Million USD | 61.867% |
| Exelixis, Inc. | 1.58 Billion USD | 86.189% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 26.785% |
| TG Therapeutics, Inc. | 198.47 Million USD | -10.414% |
| Incyte Corporation | 1.19 Billion USD | 81.592% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 79.009% |